BIOXCELERATE has revealed a new AI tool which is set to accelerate the process for identifying and developing new drugs.
It can analyse complex medical data 100 times faster than existing methods used to detect biological networks which explain disease risk and inform drug discovery.
BioXcelerate, which developed the new tool, known as PleioGraph, is a new and innovative health data science division of Optima Partners Limited.
The technology uses bioXcelerate’s own machine learning algorithms to sweep huge amounts of biological data.
It will be used to help drug developers identify the genes, proteins and cells that interact with each other to cause disease, a process known as genetic colocalization.
It provides quicker and more accurate insights about how diseases develop, helping to accelerate the drug development process.
Compared to traditional methods, PleioGraph can provide significant cost savings and reduce the amount of time patients have to wait for improved treatments and medicines.
Working with the world’s leading pharmaceutical companies, PleioGraph has processed data between 75 and 100 time faster than industry leading methods, according to bioXcelerate.
The company said that this has reduced time to insight down from months to hours.
BioXcelerate was founded by academics from the UK’s leading universities, including Cambridge, Edinburgh, Imperial College and Oxford.
The firm said it aims to bridge the gap between academia and the pharmaceutical industry by fostering a symbiotic relationship that improves health outcomes and benefits society.
Dr Chris Foley, Chief Scientist and Managing Director at bioXcelerate said: “The scale of data available is outpacing our ability to analyse it.
“Patterns explaining how diseases occur are hidden within our ever-increasing data-banks.
“AI technologies which quickly and accurately reveal these patterns are in short
supply.
“At bioXcelerate, we are providing a solution to overcome these barriers.
“Our PleioGraph technology provides an exciting, industry-leading tool to supercharge early-phase drug discovery and ultimately improve patient outcomes.”
Dr Heiko Runz, a scientific partner of Optima said: “Drug development costs are on the rise and the development of new treatments has become drawn out and costly.
“By improving efficiencies in drug discovery, we hope to accelerate the emergence of novel medicines that positively impact patients’ lives and reach them more rapidly.”
